Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Infante

Showing results (291-300 of 299) with videos related to

Pageof 30
Sort By:
You have reached the last page of results.This site can display upto 299 results.
Cancer Cell|November 14, 2018
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8<sup>+</sup> T Cell Invigoration and Polyclonal T Cell Expansion in Cancer PatientsAung Naing, Jeffrey R Infante, Kyriakos P Papadopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With TrametinibGeorgina V Long, Jeffrey S Weber, Jeffrey R Infante, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2019
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian CancerDavid E Gerber, Jeffrey R Infante, Michael S Gordon, et al.
Cell Reports|September 24, 2013
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanomaJessie Villanueva, Jeffrey R Infante, Clemens Krepler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2014
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorDouglas B Johnson, Keith T Flaherty, Jeffrey S Weber, et al.
Genome Biology and Evolution|January 24, 2018
Comparative Genomics Reveals Accelerated Evolution in Conserved Pathways during the Diversification of Anole LizardsMarc Tollis, Elizabeth D Hutchins, Jessica Stapley, et al.
Cancer Discovery|December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
Cancer Research|December 15, 2010
Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinaseArijit Chakravarty, Vaishali Shinde, Josep Tabernero, et al.
Cancer Discovery|January 30, 2013
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvementJosep Tabernero, Geoffrey I Shapiro, Patricia M LoRusso, et al.
Pageof 30

Showing results (291-300 of 299) with videos related to

Sort By:
Pageof 30
You have reached the last page of results.This site can display upto 299 results.
Cancer Cell|November 14, 2018
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8<sup>+</sup> T Cell Invigoration and Polyclonal T Cell Expansion in Cancer PatientsAung Naing, Jeffrey R Infante, Kyriakos P Papadopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With TrametinibGeorgina V Long, Jeffrey S Weber, Jeffrey R Infante, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2019
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian CancerDavid E Gerber, Jeffrey R Infante, Michael S Gordon, et al.
Cell Reports|September 24, 2013
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanomaJessie Villanueva, Jeffrey R Infante, Clemens Krepler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2014
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorDouglas B Johnson, Keith T Flaherty, Jeffrey S Weber, et al.
Genome Biology and Evolution|January 24, 2018
Comparative Genomics Reveals Accelerated Evolution in Conserved Pathways during the Diversification of Anole LizardsMarc Tollis, Elizabeth D Hutchins, Jessica Stapley, et al.
Cancer Discovery|December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
Cancer Research|December 15, 2010
Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinaseArijit Chakravarty, Vaishali Shinde, Josep Tabernero, et al.
Cancer Discovery|January 30, 2013
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvementJosep Tabernero, Geoffrey I Shapiro, Patricia M LoRusso, et al.
Pageof 30